Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionJpmorgan Chase & Co
Latest Disclosed Ownership5,198,084 shares
Ownership 5.20%
Jpmorgan Chase & Co ownership in NBIX / Neurocrine Biosciences, Inc.

2026-01-21 - Jpmorgan Chase & Co has filed an SCHEDULE 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 5,198,084 shares of Neurocrine Biosciences, Inc. (MX:NBIX). This represents 5.2 percent ownership of the company.

Jpmorgan Chase & Co has a history of taking positions in derivatives of the underlying security (NBIX) in the form of stock options. The firm currently holds call options representing 81,000 of underlying shares valued at $10,426,320 USD and put options representing 81,000 of underlying shares valued at $10,426,320 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2026-01-21 2026-01-21 13G 5,198,084 5.20

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

MX:NBIX / Neurocrine Biosciences, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COMMON 64125C109 5,442,067 241,711 4.65 700,503 -5.03 0.0049
2026-05-13 2026-03-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 0 -100.00 0
2026-02-11 2025-12-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 5,200,356 470,204 9.94 737,567 11.08 0.0463
2025-11-26 2025-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COMMON 64125C109 4,730,152 468,405 10.99 664,019 23.96 0.0398
2025-11-07 2025-09-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 4,730,152 468,405 664,019 0.0042
2025-08-12 2025-06-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 4,261,747 1,590,749 59.56 535,659 81.33 0.0350
2025-05-12 2025-03-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 2,670,998 1,299,812 94.79 295,412 57.83 0.0216
2025-02-12 2024-12-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 1,371,186 -126,745 -8.46 187,167 8.44 0.0139
2024-12-26 2024-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COMMON 64125C109 1,497,931 -864,804 -36.60 172,592 -46.94 0.0131
2024-11-08 2024-09-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 1,497,931 -864,804 172,592 0.0132
2024-12-26 2024-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COMMON 64125C109 2,362,735 67,627 2.95 325,278 2.76 0.0267
2024-08-12 2024-06-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 2,362,735 67,627 325,278 0.0267
2024-12-26 2024-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COMMON 64125C109 2,295,108 559,565 32.24 316,541 38.42 0.0267
2024-05-10 2024-03-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 2,295,108 559,565 316,541 0.0268
2024-12-26 2023-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COMMON 64125C109 1,735,543 -75,694 -4.18 228,675 12.23 0.0219
2024-02-12 2023-12-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 1,735,543 -75,694 228,675 0.0220
2023-11-14 2023-09-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 1,811,237 -150,637 -7.68 203,764 10.14 0.0225
2023-08-11 2023-06-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 1,961,874 -194,135 -9.00 185,005 -15.23 0.0201
2023-05-18 2023-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COMMON 64125C109 2,156,009 -14,053 -0.65 218,231 84,158.69 0.0266
2023-05-11 2023-03-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 2,039,988 -130,074 218,231 0.0032
2023-02-13 2022-12-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 2,170,062 -201,175 -8.48 259 -99.90 0.0342
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 2,371,237 -626,523 -20.90 251,850 -13.82 0.0362
2022-08-11 2022-06-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 2,997,760 -7,549 -0.25 292,223 3.72 0.0407
2022-05-11 2022-03-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 3,005,309 24,210 0.81 281,746 10.97 0.0339
2022-02-11 2021-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COMMON 64125C109 2,981,099 291,601 10.84 253,902 -1.57 0.0293
2022-02-10 2021-12-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 2,981,099 291,601 253,902 0.0291
2021-11-12 2021-09-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 2,689,498 1,242,324 85.84 257,949 83.15 0.0319
2021-08-12 2021-06-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 1,447,174 -88,637 -5.77 140,840 -5.70 0.0168
2021-05-12 2021-03-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 1,535,811 582,548 61.11 149,357 63.46 0.0199
2021-02-19 2020-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COMMON 64125C109 953,263 187,785 24.53 91,370 22.17 0.0134
2021-02-11 2020-12-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 953,263 187,785 91,370 2,259.6452
2020-11-12 2020-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COMMON 64125C109 765,478 43,721 6.06 74,787 -15.07 0.0126
2020-11-12 2020-09-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 765,478 74,787
2020-08-11 2020-06-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 721,757 259,846 56.25 88,055 120.26 0.0170
2020-05-12 2020-03-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 461,911 418,277 958.60 39,978 752.23 0.0094
2020-02-11 2019-12-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 43,634 12,023 38.03 4,691 64.65 0.0009
2019-11-12 2019-09-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 31,611 19,953 171.15 2,849 196.46 0.0006
2019-08-07 2019-06-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 11,658 -601,218 -98.10 961 -98.22 0.0002
2019-05-07 2019-03-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 612,876 349,164 132.40 53,995 186.73 0.0110
2019-02-11 2018-12-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 263,712 47,737 22.10 18,831 -29.09 0.0044
2018-11-13 2018-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COMMON 64125C109 215,975 -255,355 -54.18 26,555 -42.65 0.0051
2018-11-07 2018-09-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 215,975 -255,355 26,555
2018-08-14 2018-06-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 471,330 8,720 1.88 46,303 20.69 0.0095
2018-05-10 2018-03-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 462,610 -79,969 -14.74 38,364 -8.87 0.0082
2018-02-13 2017-12-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 542,579 12,331 2.33 42,099 33.66 0.0089
2017-11-09 2017-09-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 530,248 -49,773 -8.58 31,497 18.05 0.0069
2017-08-09 2017-06-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 580,021 -229,690 -28.37 26,680 -23.90 0.0061
2017-05-10 2017-03-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 809,711 -153,034 -15.90 35,061 -5.90 0.0080
2017-02-06 2016-12-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 962,745 -49,683 -4.91 37,259 -27.33 0.0090
2016-11-04 2016-09-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 1,012,428 -234,476 -18.80 51,270 -9.53 0.0126
2016-08-08 2016-06-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 1,246,904 590,549 89.97 56,671 118.33 0.0141
2016-05-10 2016-03-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 656,355 102,630 18.53 25,957 -17.14 0.0066
2016-02-12 2015-12-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 553,725 284,827 105.92 31,325 192.76 0.0079
2015-11-13 2015-09-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 268,898 -8,898 -3.20 10,700 -19.35 0.0029
2015-08-14 2015-06-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 277,796 79,823 40.32 13,268 68.76 0.0031
2015-05-15 2015-03-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 197,973 84,708 74.79 7,862 210.75 0.0018
2015-02-13 2014-12-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 113,265 113,265 0.00 2,530 0.0006
2014-08-14 2014-06-30 13F NEUROCRINE BIOSCIE COMMON 64125C109 0 -140,449 -100.00 0 -100.00
2014-05-15 2014-03-31 13F NEUROCRINE BIOSCIE COMMON 64125C109 140,449 12,450 9.73 2,261 89.21 0.0006
2014-02-26 2013-12-31 13F/A-1 NEUROCRINE BIOSCIE COMMON 64125C109 127,999 -39,117 -23.41 1,195 -36.81 0.0003
2014-02-13 2013-12-31 13F NEUROCRINE BIOSCIE COMMON 64125C109 127,999 1,195
2013-10-31 2013-09-30 13F NEUROCRINE BIOSCIE COMMON 64125C109 167,116 -8,961 -5.09 1,891 -19.74 0.0006
2013-08-13 2013-06-30 13F NEUROCRINE BIOSCIE COMMON 64125C109 176,077 176,077 2,356 0.0008
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-13 2026-03-31 13F/A NEUROCRINE BIOSCIENCES OPTION Call 81,000 170.00 10,426 145.09 n/a n/a n/a
2026-05-13 2026-03-31 13F NEUROCRINE BIOSCIENCES OPTION Call 0 -100.00 0 n/a n/a n/a
2026-02-11 2025-12-31 13F NEUROCRINE BIOSCIENCES OPTION Call 30,000 4,255 n/a n/a n/a
2025-08-12 2025-06-30 13F NEUROCRINE BIOSCIENCES OPTION Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-05-12 2025-03-31 13F NEUROCRINE BIOSCIENCES OPTION Call 57,000 0.00 6,304 -18.97 n/a n/a n/a
2025-02-12 2024-12-31 13F NEUROCRINE BIOSCIENCES OPTION Call 57,000 62.86 7,780 92.96 n/a n/a n/a
2024-12-26 2024-09-30 13F/A NEUROCRINE BIOSCIENCES OPTION Call 35,000 16.67 4,033 -2.37 n/a n/a n/a
2024-11-08 2024-09-30 13F NEUROCRINE BIOSCIENCES OPTION Call 35,000 4,033 n/a n/a n/a
2024-12-26 2024-06-30 13F/A NEUROCRINE BIOSCIENCES OPTION Call 30,000 4,130 n/a n/a n/a
2024-08-12 2024-06-30 13F NEUROCRINE BIOSCIENCES OPTION Call 30,000 4,130 n/a n/a n/a
2021-11-12 2021-09-30 13F NEUROCRINE BIOSCIENCES OPTION Call 0 -100.00 0 -100.00 n/a n/a n/a
2021-08-12 2021-06-30 13F NEUROCRINE BIOSCIENCES OPTION Call 25,000 0.00 2,433 0.08 n/a n/a n/a
2021-05-12 2021-03-31 13F NEUROCRINE BIOSCIENCES OPTION Call 25,000 -40.19 2,431 -39.33 n/a n/a n/a
2021-02-19 2020-12-31 13F/A NEUROCRINE BIOSCIENCES OPTION Call 41,800 4,007 n/a n/a n/a
2021-02-11 2020-12-31 13F NEUROCRINE BIOSCIENCES OPTION Call 41,800 4,007 n/a n/a n/a
2019-08-07 2019-06-30 13F NEUROCRINE BIOSCIENCES OPTION Call 0 -100.00 0 -100.00 n/a n/a n/a
2019-05-07 2019-03-31 13F NEUROCRINE BIOSCIENCES OPTION Call 257,100 471.33 22,651 604.98 n/a n/a n/a
2019-02-11 2018-12-31 13F NEUROCRINE BIOSCIENCES OPTION Call 45,000 3,213 n/a n/a n/a
2018-08-14 2018-06-30 13F NEUROCRINE BIOSCIENCES OPTION Call 0 -100.00 0 -100.00 n/a n/a n/a
2018-05-10 2018-03-31 13F NEUROCRINE BIOSCIENCES OPTION Call 30,000 2,488 n/a n/a n/a
2016-11-04 2016-09-30 13F NEUROCRINE BIOSCIENCES OPTION Call 0 -100.00 0 -100.00 n/a n/a n/a
2016-08-08 2016-06-30 13F NEUROCRINE BIOSCIENCES OPTION Call 32,800 118.67 1,491 151.43 n/a n/a n/a
2016-05-10 2016-03-31 13F NEUROCRINE BIOSCIENCES OPTION Call 15,000 593 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-13 2026-03-31 13F/A NEUROCRINE BIOSCIENCES OPTION Put 81,000 170.00 10,426 145.09 n/a n/a n/a
2026-05-13 2026-03-31 13F NEUROCRINE BIOSCIENCES OPTION Put 0 -100.00 0 n/a n/a n/a
2026-02-11 2025-12-31 13F NEUROCRINE BIOSCIENCES OPTION Put 30,000 4,255 n/a n/a n/a
2025-08-12 2025-06-30 13F NEUROCRINE BIOSCIENCES OPTION Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-05-12 2025-03-31 13F NEUROCRINE BIOSCIENCES OPTION Put 57,000 0.00 6,304 -18.97 n/a n/a n/a
2025-02-12 2024-12-31 13F NEUROCRINE BIOSCIENCES OPTION Put 57,000 90.00 7,780 125.12 n/a n/a n/a
2024-12-26 2024-09-30 13F/A NEUROCRINE BIOSCIENCES OPTION Put 30,000 0.00 3,457 -16.32 n/a n/a n/a
2024-11-08 2024-09-30 13F NEUROCRINE BIOSCIENCES OPTION Put 30,000 3,457 n/a n/a n/a
2024-12-26 2024-06-30 13F/A NEUROCRINE BIOSCIENCES OPTION Put 30,000 4,130 n/a n/a n/a
2024-08-12 2024-06-30 13F NEUROCRINE BIOSCIENCES OPTION Put 30,000 4,130 n/a n/a n/a
2022-08-11 2022-06-30 13F NEUROCRINE BIOSCIENCES OPTION Put 0 -100.00 0 -100.00 n/a n/a n/a
2022-05-11 2022-03-31 13F NEUROCRINE BIOSCIENCES OPTION Put 4,000 375 n/a n/a n/a
2021-05-12 2021-03-31 13F NEUROCRINE BIOSCIENCES OPTION Put 0 -100.00 0 -100.00 n/a n/a n/a
2021-02-19 2020-12-31 13F/A NEUROCRINE BIOSCIENCES OPTION Put 400,000 -13.04 38,340 -14.69 n/a n/a n/a
2021-02-11 2020-12-31 13F NEUROCRINE BIOSCIENCES OPTION Put 400,000 38,340 n/a n/a n/a
2020-11-12 2020-09-30 13F/A NEUROCRINE BIOSCIENCES OPTION Put 460,000 44,942 n/a n/a n/a
2020-11-12 2020-09-30 13F NEUROCRINE BIOSCIENCES OPTION Put 460,000 44,942 n/a n/a n/a
2019-08-07 2019-06-30 13F NEUROCRINE BIOSCIENCES OPTION Put 0 -100.00 0 -100.00 n/a n/a n/a
2019-05-07 2019-03-31 13F NEUROCRINE BIOSCIENCES OPTION Put 83,600 85.78 7,365 129.23 n/a n/a n/a
2019-02-11 2018-12-31 13F NEUROCRINE BIOSCIENCES OPTION Put 45,000 3,213 n/a n/a n/a
2018-08-14 2018-06-30 13F NEUROCRINE BIOSCIENCES OPTION Put 0 -100.00 0 -100.00 n/a n/a n/a
2018-05-10 2018-03-31 13F NEUROCRINE BIOSCIENCES OPTION Put 30,000 2,488 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.